Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc > $HMTXF flooding the entire market with returns in galore

<< Previous

Bullboard Posts

Next >>

Post by anthonysolleon Jul 13, 2022 3:29pm

145 Views

Post# 34821872

$HMTXF flooding the entire market with returns in galore

$HMTXF is gallantly pacing forward with all the necessities to fight the market flux and is resolute to breakout broadly again, the shares are trading with a substantial spike at $0.167.

<< Previous

Bullboard Posts

Next >>

Gold, growth and sustainability in focus for Mandalay Resources